

1/4/98

1 of 5

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: January 9, 1998

ATTY DOCKET NO.
038007/0112

SERIAL NO.
Unassigned 09/005,035

APPLICANT
Peter K. LAW

FILING DATE
January 9, 1998

GROUP
Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
WAB	A1	4,542,148 4,542,443	9/1985	Hosokawa et al.	514	356	
WAB	A2	5,139,481	08/1992	Faustman et al.	604	49	
WAB	A3	4,154,652	05/1979	Sawamura et al.	195	1.8	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WAB	A4	93/17697 ✓	09/1993	WIPO	—	—	
WAB	A5	95/14079 ✓	05/1995	WIPO	—	—	
WAB	A6	96/38544 ✓	12/1996	WIPO	—	—	

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

WAB	A7	—	Morgan, "Cell and Gene Therapy in Duchenne Muscular Dystrophy", Human Gene Therapy, Vol. 5, pp. 165-173, (1994)
	A8		Maltsev et al., "Embryonic Stem Cells Differentiate in vitro into Cardiomyocytes Representing Sinusnodal, Atrial and Ventricular Cell Types", Mech. Devl., Vol. 44, pp. 41-50, (1993)
	A9		Koh et al., "Long-term Survival of AT-1 Cardiomyocyte Grafts in Syngeneic Myocardium", Am. J. Physiol, Vol. 264, pp. 1727-1733, (1993)
	A10		Watson et al., "Working Toward Human Gene Therapy: Recombinant DNA", New York, W.H. Freeman & Co., pp. 576, (1992)
WAB	A11		Entrikin et al., "Drugs in Muscular Dystrophy of the Chicken: Corticosterone-21 Acetate; Nerve & Muscle, (1984)

EXAMINER *W. H. [Signature]* DATE CONSIDERED 1/15/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet <u>2</u> of <u>5</u> FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: January 9, 1998		ATTY DOCKET NO. 038007/0112 APPLICANT Peter K. LAW FILING DATE January 9, 1998		SERIAL NO. Unassigned <u>09/005035</u> GROUP Unassigned	
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)					
	A19		C.A. Bonsett, Duchenne Muscular Dystrophy-A Rational Approach to Disease Comprehension and Therapy", Indiana Medicine, March, 1986		
	A20		Lee et al., "Mdx Transgenic Mouse: Restoration of Recombinant Dystrophin to the Dystrophic Muscle", Human Gene Therapy, (1993)		
	A21		Rowland, "Prednisone in Duchenne Muscular Dystrophy", The Lancet, February 15, 1975		
	A22		Wolfe et al., "Direct Gene Transfer into Mouse Muscle in Vivo", Science, Vol. 274, pp. 1465-1468, (1990)		
	A23		Folkers et al., "Treatment of Preclinical Muscular Dystrophy with Coenzyme Q", Excerpta Med. Int. Service, Vol. 334, p. 158, (1974)		
	A24		Law, "Reduced Regenerative Capability of Dystrophic Mouse Muscle", Exp. Neurol, Vol. 60, pp. 231-43, (1978)		
	A25		Young et al., "Histochemical Analysis of Newly Synthesized and Accumulated Sulfated Glycosaminoglycans During Musculogenesis in the Embryonic Chick Leg.", J. Morph, Vol. 201, pp. 85-103, (1989)		
	A26		Jackman et al., "Catheter Recordings of Accessory Atrioventricular Pathway Activation...", From Cell to Bedside, pp. 491-502, (1990)		
	A27		Soonpaa et al., "Formation of Nascent Intercalated Disks Between Grafted Fetal Cardiomyocytes and Host Myocardium", Science, pp. 264-98, (1994)		
	A28		Huard et al., "Human Myoblast Transplantation in Immunodeficient and Immunosuppressed Mice: Evidence of Rejection Muscle Nerve", Vol. 17, pp. 224-34, (1994)		
	A29		Roy et al., "Antibody Formation After Myoblast Transplantation in Duchenne-Dystrophic Patients, Donor HLA Compatible", Transpl. Proc., Vol. 25, pp. 995-7, (1993)		
	A30		Huard et al., "Human Myoblast Transplantation Between Immunohistocompatible Donors and Recipients Produces Immune Reactions", Transpl. Proc., Vol. 24, pp. 3049-51, (1992)		
	A31		Law et al., "Pathogenesis and Treatment of Hereditary Muscular Dystrophy", Kakulas BA, Mastalgia, pp. 101-18, (1990)		
EXAMINER			DATE CONSIDERED <u>1/15/01</u>		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: January 9, 1998

ATTY DOCKET NO.
038007/0112SERIAL NO.
Unassigned

09/005,035

APPLICANT
Peter K. LAWFILING DATE
January 9, 1998GROUP
Unassigned

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

MS	A32	Law et al., "Myoblast Injection Method Regulates Cell Distribution and Fusion",
		Transpl. Proc. in Press (No Date Provided)
	A33	Law et al., "New Muscle Transplant Method Produces Normal Twitch Tension in Dystrophic Muscle", Muscle Nerve, Vol. 2, pp. 356-63 (1979).
	A34	Law et al., "Feasibility, Safety, and Efficacy of Dystrophy Boys", Cell Transplantation, Vol. 1, pp. 235-44, (1992)
	A35	Law et al., "Cell Transplantation as an Experimental Treatment for Duchenne Muscular Dystrophy", Cell Transplantation, Vol. 3, pp. 485-503, (1993)
	A36	Peterson, "Chimaera Mouse Study Shows absence of Disease in Genetically Dystrophic Muscle", Nature, Vol. 248, pp. 561-4, (1974)
	A37	Hogan et al., "Manipulating the Mouse Embryo", A Laboratory Manual, Cold Spring Harbor Laboratory, (1986)
	A38	Cox et al., "Overexpression of Dystrophin in Transgenic MDX Mice Eliminates Dystrophic Symptoms Without Toxicity", Nature, Vol. 364, pp. 725-9, (1993)
	A39	Milhorat, "Therapy in Muscular Dystrophy Medical Annals of the District of Columbia", Vol. 23, pp. 15, (1954)
	A40	Wood, "New Therapeutic Directions in Duchenne Muscular Dystrophy Following Discovery of Dystrophin", Pathogenesis and Therapy of Duchenne and Becker, Muscular Dystrophy, Raven Press, pp. 85-99 (1990).
	A41	Annals of the District of Columbia Vol. 23, pp. 15, (1954)
	A42	Van Meter, "Progressive Muscular Dystrophy", Calif. Med., Vol. 79, pp. 297-99, (1990)
V	A43	Nakahara, "Studies on Progressive Muscular Dystrophy", Arzneim. Forsch., Vol. 15, pp. 591-95, (1965)
WLB	A44	Drachman et al., "Prednisone in Duchenne Muscular Dystrophy", Lancet, Vol. 2, pp. 1409-12, (1974)
EXAMINER WLB		DATE CONSIDERED 1/15/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: January 9, 1998

ATTY DOCKET NO.
038007/0112SERIAL NO.
~~Unassigned~~ 09/005,035APPLICANT
Peter K. LAWFILING DATE
January 9, 1998GROUP
Unassigned

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

WKS	A45		Coakley et al., "Mazindol in Duchenne Muscular Dystrophy",
			Lancet, Vol. 1, No. 8578, pp. 184, (1988)
	A46		Munsat et al., "Prednisone in Duchenne Muscular Dystrophy",
			Lancet, Vol. 1, pp. 276-77, (1985)
	A47		Siegel et al., "Failure of Corticosteroid in the Treatment of Duchenne (Pseudo-Hypertrophic) Muscular
			Dystrophy", I.M.J., Vol. 145, pp. 32-33, (1974)
	A48		Acsadi et al., "Human Dystrophin Expression in MDX Mice After Intramuscular Injection of DNA Constructs",
			Nature, Vol. 352, pp. 815-18, (1991)
	A49		Neumeyer et al., "Arterial Delivery of Myoblasts to Skeletal Muscle",
			Neurology, Vol. 42, pp. 2258-62, (1992)
	A50		Smith et al., "Genes Transferred by Retroviral Vectors into Normal and Mutant Myoblasts in Primary Cultures
			Are Expressed in Myotubes", Mol. & Cell. Biol., Vol. 10, pp. 3268-71, (1990)
	A51		Hyde et al., "Correction of the Ion Transport Defect in Cystic Fibrosis Transgenic Mice by Gene Therapy",
			Nature, Vol. 362, pp. 250-55, (1993)
	A52		Hoffman et al., "Dystrophin: The Protein Product of the Duchenne Muscular Dystrophy",
			Locus. Cell, Vol. 51, pp. 919-28, (1987)
	A53		Chen et al., "Dystrophin Cytochemistry in MDX Mouse Muscles Injected with Labeled Normal Myoblasts",
			Cell Transplantation, Vol. 1, pp. 17-22, (1992)
	A54		Partridge et al., "Conversion of MDX Myofibers From Dystrophin-Negative to Positive by Injection of Normal
			Myoblasts", Nature, Vol. 337, pp. 116-17, (1989)
	A55		Gussoni et al., "Normal Dystrophin Transcripts Detected in Duchenne Muscular Dystrophy Patients After
			Myoblast Transplantation", Nature, Vol. 365, pp. 435-38, (1992)
	A56		Huard et al., "Myoblast Transplantation Produced Dystrophin-Positive Muscle Fibers in a 16-Year-Old Patient
			with Duchenne Muscular Dystrophy", Clin. Sci., Vol. 81, pp. 287-88, (1991)
WKS	A57		Huard et al., "Human Myoblast Transplantation: Preliminary Results of 4 Cases",
			Muscle Nerve, Vol. 15, pp. 550-60, (1992)
EXAMINER WKS			DATE CONSIDERED 1/15/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet <u>5</u> of <u>5</u> FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: January 9, 1998		ATTY DOCKET NO. 038007/0112 APPLICANT Peter K. LAW FILING DATE January 9, 1998		SERIAL NO. Unassigned 09/005,035 GROUP Unassigned	
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)					
<i>WKS</i>	A58		Law et al., "Dystrophin Production Induced by Myoblast Transfer Therapy in Duchenne Muscular Dystrophy",		
			Lancet, Vol. 336, pp. 114-15, (1990)		
↓	A59		Law et al., "Myoblast Transfer for Duchenne Muscular Dystrophy",		
			Acta Paediatrica, Japan, Vol. 33, pp. 206-15, (1991)		
↓	A60		Law et al., "Myoblast Transfer Therapy for Duchenne Muscular Dystrophy",		
			Advances in Clinical Neurosciences, Vol. 2, pp. 463-70, (1992)		
↓	A61		Law et al., "Pioneering Development in Myoblast Transfer Therapy", Muscular Dystrophy Research,		
			Elsevier Science Publishers, pp. 109-11, (1991)		
↓	A62		Law et al., "Long-Term Improvement in Muscle Function, Structure and Biochemistry Following Myoblast		
			Transfer in DMD", Acta Cardiologica, Vol. 3, pp. 281-301, (1991)		
↓	A63		Law, "Beneficial Effects of Transplanting Normal Limb-Bud Mesenchyme Into Dystrophic Mouse Muscles",		
			Nerve and Muscle, Vol. 5, pp. 619-27, (1982)		
↓	A64		Law et al., "Histoincompatible Myoblast Injection Improves Muscle Structure and Function of Dystrophic Mice",		
			Transplantation Proceedings, Vol. XX, No.3, Supp. 3, pp. 1144-19, June (1988)		
↓	A65		Law, "Myoblast Transfer Improves Muscle Genetics/Structure/Function and Normalizes the Behavior and Life		
			Span of Dystrophic Mice", Myoblast Transfer Therapy. <i>New: Plenum Press; 75-87 (1990).</i>		
↓	A66		Law et al., "Normal Myoblast Injections Provide Genetic Treatment for Murine Dystrophy",		
			Nerve & Muscle, Vol. 11, pp. 525-33, (1988)		
↓	A67		Barr et al., "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts",		
			Science, Vol. 254, pp. 1507-9, (1991)		
<i>WKS</i>	A68		Karpati et al., "Dystrophin is Expressed in MDX Skeletal Muscle Fibers After Normal Myoblast Implantation",		
			American journal of Pathology, Vol. 135, No. 1, July (1989)		
EXAMINER <i>W. P. H.</i>			DATE CONSIDERED <i>1/15/01</i>		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.